OCO. Yu. Chukhrai

O. Yu. Chukhrai

*This is an algorithmically generated author record based on publicly available information.

O. Yu. Chukhrai has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy

    by L.V. Moskvina, G.A. Raskin, N.A. Savelov, Ya.V. Vishnevskaya, L.E. Zavalishina, D.O. Zagvozkina, A.G. Kudaibergenova, D.A. Tsekatunov, O.YU. Chukhray, A.YU. Shamanova, et al.

    This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.

  • Open Access

    Clinical and morphological features of mantle cell lymphoma as a cause of ascites

    by A. A. Serdyuk, A. V. Larionova, D. A. Rabadanov, O. Y. Chukhrai, T. V. Chitanava, О. Ю. Чухрай

    The article describes a rare clinical case of hydroperitoneum in a patient with mantle cell lymphoma. This observation illustrates the diagnostic difficulties in identifying the cause of ascites of unclear etiology and emphasizes the important role of cytological analysis of ascitic fluid. Mantle cell lymphoma is an aggressive mature B-cell lymphoma characterized by the proliferation of abnormal lymphoid cells with typical indolent nuclear circuits. Although extranodal involvement is not uncommon for a given vila lymphoma, the isolated occurrence of ascites as the first manifestation of the disease presents a unique and complex diagnostic situation. The purpose of this clinical example was to demonstrate the importance of including oncological and hematological diseases in the differential diagnostic search for ascites, especially when standard methods (for example, imaging diagnostic methods, biochemical tests) do not reveal an obvious cause. The work analyzes in detail the clinical case of a patient with hydroperitoneum, where a comprehensive diagnostic approach was applied, including ultrasound examination, laboratory tests and, most importantly, cytological and immunophenotypic examination of peritoneal fluid. Cytological analysis of ascitic fluid revealed the presence of atypical lymphoid cells, which made it possible to establish the diagnosis of mantle cell lymphoma with peritoneal damage. This diagnostic method has become key for determining the tactics of patient management and the timely start of specific polychemotherapy. Early detection of specific cells in ascitic fluid allows for an accurate diagnosis, determination of the stage of the disease and immediate initiation of appropriate treatment, ultimately improving the prognosis for the patient.

  • Open Access

    Survival of Patients With Primary Cutaneous Melanoma (Stages 0-IIА and IIB-IIC), Depending on the Presence of the BRAF Mutation in the Tumor and Surgical Treatment Option

    by S. A. Yаrgunin, I. V. Reshetov, Ya. N. Shoykhet, S. I. Samoylova, O. Yu. Chukhrai, S. N. Pyatakov, V. S. Yаrgunin, Я. Н. Шойхет, О. Ю. Чухрай

    Background: Cutaneous melanoma is an extremely aggressive disease with an unpredictable prognosis. Even among patients with similar tumor parameters and extent of surgical treatment, survival may vary. The extent of surgical resection of primary cutaneous melanoma is well-established, and a BRAF mutation in the tumor is an unfavorable prognostic factor for patient survival. The mutation presence is mainly used as a marker for prescribing targeted therapy. The impact of the extent of surgery and the method for restoring a tissue defect on survival of patients with similar stages remains unexplored. The impact of the BRAF mutation in the tumor on survival of patients with cutaneous melanoma depending on the surgery method has also not been studied. We analyzed the surgical treatment outcomes of 221 patients with primary cutaneous melanoma (stages 0-IIA and IIB-IIC) who were found to have the BRAF mutation and underwent different extents of tumor excision with closure of the surgical tissue defect.Objective: To analyze the impact of the BRAF mutation in the tumor on 5-year survival of patients with primary cutaneous melanoma (stages 0-IIA and IIB-IIC), depending on the extent of surgery and the method of replacing the tissue defect.Materials and methods: We used data from 221 patients with primary cutaneous melanoma (stages 0-IIA and IIB-IIC) and assessed their BRAF mutation status, extent of tumor excision, and method of closing the tissue defect. The patients were divided into 2 groups: the main group (wide excision of the tumor and plastic replacement of the tissue defect) and the comparison group (standard margin and linear closure of the tissue defect). After surgery, all the patients underwent tumor analysis for the BRAF p.V600E/K mutation using real-time PCR. DNA was isolated using the cobas® DNA Sample Preparation Kit on a cobas® z 480 analyzer. We used the following statistical methods: frequency analysis, z test to check the equality, and Kaplan-Meier survival analysis and such software as MedCalc 12.5 (1993-2013, MedCalc Software) and SPSS 26 (IBM Corp, 2019, IBM SPSS Statistics for Windows, Armonk, NY, USA). Results: Wide excision of primary cutaneous melanoma (stages 0-IIA and IIB-IIC) was found to increase 5-year progression-free survival in patients with subsequent plastic replacement of the tissue defect compared with patients with standard margin and linear closure of the tissue defect and 5-year overall survival in patients with stage 0-IIA melanoma. In patients with 0-IIA stage melanoma and positive BRAF mutation test results, wide excision with reconstructive and plastic defect closure improved the 5-year progression-free survival. Conclusions: The 5-year progression-free survival and 5-year overall survival increased by 20.9% (P = .005) and 13.0% (P = .031), respectively, in patients who underwent wide excision of primary cutaneous melanoma followed by plastic replacement of the tissue defect compared with patients with standard excision of primary tumors and linear closure of the tissue defect. The 5-year progression-free survival increased by 23.7% (P = .017) in patients with stage IIB-IIC melanoma, regardless of the BRAF mutation. In patients with 0-IIa stage melanoma and positive BRAF mutation test results who underwent wide excision, the 5-year progression-free survival increased by 20.7% (P = .047) compared with patients who underwent tumor excision with a standard margin.

  • Open Access

    Survival of Patients With Primary Cutaneous Melanoma and the Surgical Treatment Option Based on the Level of the Surface Protein PD-L1 in the Tumor Tissue

    by S. S. Yargunin, I. V. Reshetov, Ya. N. Shoykhet, S. I. Samoylova, O. Yu. Chukhrai, S. N. Pyatakov, Я. Н. Шойхет, О. Ю. Чухрай

    Background: The PD-­L1 level is mainly used to predict the effect of drug treatment in patients with melanoma. Despite the radical nature of surgery in these patients, the rate of disease progression remains high. Therefore, it is important to study the relation between the PD-­L1 level in the tumor and surgical treatment options for cutaneous melanoma and patient survival.Objective: To analyze the effect of the PD-­L1 level in patients with primary cutaneous melanoma at different levels of tumor excision and options for closing the surgical defect.Materials and methods: We used data of 143 patients with stage 0­IIIC primary cutaneous melanoma who were randomized into 2 groups: the main group (wide excision of the tumor and plastic repair of the tissue defect) and the comparison group (standard tumor removal) with different PD-­L1 levels (IC [immune cells] %). The 5­-year survival of patients was estimated.Results: We found the mutual dependence of the PD­-L1 level and the survival of patients with stage 0-­IIC melanoma on the extent of the tissues removed and the option for closing the defect.Conclusions: The 5­year progression­free survival in patients with stage 0­IIA primary cutaneous melanoma was higher than that of those with stage IIB-­IIC melanoma regardless of the PD-­L1 level. In patients with stage 0-­IIA primary cutaneous melanoma and the low PD-­L1 level (˂5), progression­free survival was 26.3% higher (P = .013) than that of those with the high PD-­L1 level (≥5). In patients from the main group with stage 0-­IIA melanoma and the low PD­L1 level (˂5), progression­free survival was 25% higher (P = .017) and overall survival was 16.7% higher (P = .045) compared with patients from the control group with the same PD-­L1 level. In patients from the main group with stage 0­-IIC melanoma and the high PD­-L1 level (≥5), the 5-­year progression­free survival was 21.2% higher (P = .033) compared with patients from the comparison group.

  • Open Access

    Organization clinical decision-making programs in the local practice of the region: problematic issues that determine the choice of therapy in the progression of endometrial cancer

    by A. Yu. Goryainova, M. G. Leonov, R. A. Murashko, O. S. Tsirulnikova, O. Yu. Chukhrai, А. Ю. Горяинова, О. Ю. Чухрай

    Introduction. For the treatment of uterine body cancer (UBC), modern oncologists have at their disposal clinical recommendations of scientific communities, the set of drug options in which is represented by a limited range of drugs that have not been studied enough (phase II studies, no more than 52 patients in each). There is an obvious lack of information about clinical routine data systematization algorithms that describe the molecular biological features of the tumor, its prevalence, patient characteristics, existing treatment models, and form a decision-making program when planning the treatment of UBC patients.Aim. Тo develop an algorithm for routing patients with UBC on the territory of the Krasnodar Region in the existing conditions for organizing medical care and human resources.Materials and methods. Local observational retrospective study. Sources – medical records. The data were collected by the co-authors of the article in the course of daily clinical activities. Information from the medical records of 72 patients with endometrial cancer who were referred for microsatellite instability (MSI) testing at the Oncological Dispensary of Krasnodar from 01/01/2021 to 11/16/2022 was analyzed to determine the possibility of receiving immuno/immuno-targeted therapy in the second and subsequent lines medicinal treatment.Results. In the Krasnodar Oncological Dispensary all the therapy options specified in the clinical guidelines were used. One line of systemic therapy for a common disease was received by 61 patients out of 72, only 41 patients received the second line, and only 19 patients received the third line. Five patients received the immunotargeted combination in the second line and 3 in the third. One patient received immunotherapy with pembrolizumab in the third line. One patient received immunotherapy with pembrolizumab in the third line. An analysis of the factors influencing the possibility of receiving this therapy showed the importance of timely genetic testing of MSI, as well as related organizational issues, such as the ability to quickly receive treatment and ensure appropriate follow-up of patients.Conclusions. Based on the study, low awareness of clinicians about the possibility and necessity of early testing for the presence of MSI in an endometrial tumor was revealed. The organization of delivery of material from clinics that have a territorial remoteness, insufficient access to patient consultations by related specialists, and low patient compliance limit the introduction of modern methods of therapy for UBC patients. Establishing a system of close professional interaction between physicians will contribute to a wider introduction of new methods of diagnosis and treatment of UBC patients.

  • Excised tumor checklist in cutaneous melanoma diagnostics

    by S.A. Yargunin, O.YU. Chukhrai

    Целью исследования было проанализировать влияние наглядного алгоритма описания пигментного образования на полноту описательной части, влияющей на формирование окончательного диагноза после оперативного лечения по поводу первичной или распространенной меланомы кожи. Материал и методы: исследовались пациенты с первичной и метастатической меланомой кожи (МК), пролеченные в 2009-2010 и 2013 годах (n=616), которые были рандомизированы на 2 группы методом слепого отбора на основную (n=275), в которой при описании гистологического препарата применялся наглядный алгоритм в виде бланка и группу сравнения (n= 341), в которой использована свободная форма описательной части. Результаты: установлено, что предложенный нами алгоритм в виде бланка позволяет улучшить описание опухоли от 2,6% до 99,6% по необходимым пунктам установки достоверного окончательного диагноза, что практически исключает уточняющие пересмотры гистологического материала. Обсуждение: выявлена зависимость полноты описания ключевых пунктов гистологического материала при первичной и метастатической меланоме кожи от использования алгоритма в виде унифицированного бланка регистрации. Информативность описания первичной опухоли улучшилась: в типе опухоли - на 2,6% (р=0,012), уровне инвазии по Кларку - на 4,1% (р=0,002), толщине по Бреслоу - на 6,0% (р˂0,001), наличия изъязвления - на 63,4% (р˂0,001), уровня лимфоидной инфильтрации - на 46,6% (р˂0,001), описания линии резекции - на 91,8% (р˂0,001), митозов в опухоли - на 82,1% (р˂0,001), описания периневральной инвазии - на 98,9% (р˂0,001), сосудистой инвазии - на 99,2% (р˂0,001), наличия или отсутствия транзиторных/сателлитных МТС - на 99,6% (р˂0,001). Заключение: использование алгоритма описания пигментного образования, в том числе первичной и метастатической меланомы кожи практически полностью исключает влияние человеческого фактора на включение или исключение диагноз-формирующих пунктов в описательной части гистологического...